Dr. Eric Van Cutsem discusses how trastuzumab may be able to provide a significant survival advantage for gastric cancer patients whose tumors carry the HER2 receptor. Neil Osterweil of Global Medical News Network (GMNN) reports from the annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
All Comments